BioArctic partner Eisai launches Leqembi Pen in Japan
BIOA•BIOA•BIOA•BIOA•Eisai launched Leqembi Pen in Japan on November 13, 2026, for early Alzheimer’s disease. The weekly 500 mg autoinjector is Japan’s first anti-amyloid treatment available for home administration and is covered by national health insurance.
BioArctic’s partner Eisai launched Leqembi Pen in Japan on November 13, 2026, for early Alzheimer’s disease. Japan is the second launch market after the United States, and the treatment is included in Japan’s national health insurance drug price list.
Approved in Japan on September 16, 2026, Leqembi Pen is the country’s first anti-amyloid treatment available for home administration. The autoinjector delivers a weekly 500 mg dose using two pens, as an alternative to intravenous treatment every two weeks.
BioArctic receives royalties on global sales and sales milestone payments, with no lecanemab development costs for Alzheimer’s disease.
